FDA Priority Review granted based on positive results from IMROZ phase 3 study
If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care treatment for patients with newly diagnosed transplant-ineligible multiple myeloma
Pivotal IMROZ phase 3 study results to be featured during oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.